208 related articles for article (PubMed ID: 38454502)
1. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology.
Silva-Spínola A; Leitão MJ; Nadal A; Le Bastard N; Santana I; Baldeiras I
Alzheimers Res Ther; 2024 Mar; 16(1):51. PubMed ID: 38454502
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
3. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid Alzheimer's Disease Biomarker Patterns of Change Prior to the Onset of Mild Cognitive Impairment.
Sun Y; Moghekar A; Soldan A; Pettigrew C; Greenberg B; Albert M; Wang MC;
J Alzheimers Dis; 2023; 96(1):287-300. PubMed ID: 37742656
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
6. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
[TBL] [Abstract][Full Text] [Related]
7. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
8. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR
Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
11. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
[TBL] [Abstract][Full Text] [Related]
12. The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "In Vivo" in the Differential Diagnosis of Alzheimer's Dementia.
Santangelo R; Dell'Edera A; Sala A; Cecchetti G; Masserini F; Caso F; Pinto P; Leocani L; Falautano M; Passerini G; Martinelli V; Comi G; Perani D; Magnani G
Curr Alzheimer Res; 2019; 16(7):587-595. PubMed ID: 31345148
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
[TBL] [Abstract][Full Text] [Related]
14. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
16. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
18. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
19. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
Karikari TK; Emeršič A; Vrillon A; Lantero-Rodriguez J; Ashton NJ; Kramberger MG; Dumurgier J; Hourregue C; Čučnik S; Brinkmalm G; Rot U; Zetterberg H; Paquet C; Blennow K
Alzheimers Dement; 2021 May; 17(5):755-767. PubMed ID: 33252199
[TBL] [Abstract][Full Text] [Related]
20. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
